Your browser doesn't support javascript.
loading
New development of lipid-lowering therapy of coronary heart disease: Inclisiran / 中国临床药理学与治疗学
Article en Zh | WPRIM | ID: wpr-1014854
Biblioteca responsable: WPRO
ABSTRACT
Because of high rate of nonadherence to statins, the subcutaneously injection of Inclisiran therapy intervals are from 3 months to 6 months, which will increase the patients' adherence to the Inclisiran therapy. In this review, we summarize the latest advances of Inclisiran, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Inclisiran. Finally, we discuss the current status of Inclisiran in the clinical works.
Palabras clave
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Chinese Journal of Clinical Pharmacology and Therapeutics Año: 2022 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Chinese Journal of Clinical Pharmacology and Therapeutics Año: 2022 Tipo del documento: Article